142 related articles for article (PubMed ID: 23397607)
1. Reply to “Response to “CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype”. Haematologica 2012;97(7):1110-1114.
Paíno T; Paiva B; San Miguel J
Haematologica; 2013 Jan; 98(1):e10. PubMed ID: 23397607
[No Abstract] [Full Text] [Related]
2. Response to "CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype". Haematologica 2012;97(7):1110-4.
Van Hoef ME
Haematologica; 2013 Jan; 98(1):e11. PubMed ID: 23277593
[No Abstract] [Full Text] [Related]
3. CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype.
Paíno T; Ocio EM; Paiva B; San-Segundo L; Garayoa M; Gutiérrez NC; Sarasquete ME; Pandiella A; Orfao A; San Miguel JF
Haematologica; 2012 Jul; 97(7):1110-4. PubMed ID: 22315496
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells.
Kawano Y; Kikukawa Y; Fujiwara S; Wada N; Okuno Y; Mitsuya H; Hata H
Int J Oncol; 2013 Dec; 43(6):1809-16. PubMed ID: 24126540
[TBL] [Abstract][Full Text] [Related]
5. Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma.
Kotouček PP; Orfao A
Br J Haematol; 2014 Aug; 166(3):466-7. PubMed ID: 24689340
[No Abstract] [Full Text] [Related]
6. Hypoxia promotes stem cell-like phenotype in multiple myeloma cells.
Muz B; de la Puente P; Azab F; Luderer M; Azab AK
Blood Cancer J; 2014 Dec; 4(12):e262. PubMed ID: 25479569
[No Abstract] [Full Text] [Related]
7. Rituximab in CD20 positive multiple myeloma.
Moreau P; Voillat L; Benboukher L; Mathiot C; Dumontet C; Robillard N; Hérault O; Garnache F; Garand R; Varoqueaux N; Avet-Loiseau H; Harousseau JL; Bataille R;
Leukemia; 2007 Apr; 21(4):835-6. PubMed ID: 17268523
[No Abstract] [Full Text] [Related]
8. [Identification and targeting of multiple myeloma stem cells].
Hosen N
Nihon Rinsho; 2015 May; 73(5):816-22. PubMed ID: 25985637
[TBL] [Abstract][Full Text] [Related]
9. The myeloma stem cell concept, revisited: from phenomenology to operational terms.
Johnsen HE; Bøgsted M; Schmitz A; Bødker JS; El-Galaly TC; Johansen P; Valent P; Zojer N; Van Valckenborgh E; Vanderkerken K; van Duin M; Sonneveld P; Perez-Andres M; Orfao A; Dybkær K
Haematologica; 2016 Dec; 101(12):1451-1459. PubMed ID: 27903712
[TBL] [Abstract][Full Text] [Related]
10. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
Matsui W; Wang Q; Barber JP; Brennan S; Smith BD; Borrello I; McNiece I; Lin L; Ambinder RF; Peacock C; Watkins DN; Huff CA; Jones RJ
Cancer Res; 2008 Jan; 68(1):190-7. PubMed ID: 18172311
[TBL] [Abstract][Full Text] [Related]
11. Cytogenetic Study and Analysis of Protein Expression in Plasma Cell Myeloma with t(11;14)(q13;q32): Absence of BCL6 and SOX11, and Infrequent Expression of CD20 and PAX5.
Yokoi S; Sakai H; Uchida A; Uemura Y; Sato K; Tsuruoka Y; Nishio Y; Matsunawa M; Suzuki Y; Isobe Y; Kato M; Inoue Y; Hoshikawa M; Miura I
J Clin Exp Hematop; 2015; 55(3):137-43. PubMed ID: 26763361
[TBL] [Abstract][Full Text] [Related]
12. Concise review: Defining and targeting myeloma stem cell-like cells.
Abe M; Harada T; Matsumoto T
Stem Cells; 2014 May; 32(5):1067-73. PubMed ID: 24449391
[TBL] [Abstract][Full Text] [Related]
13. A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells.
Rossi EA; Rossi DL; Stein R; Goldenberg DM; Chang CH
Cancer Res; 2010 Oct; 70(19):7600-9. PubMed ID: 20876805
[TBL] [Abstract][Full Text] [Related]
14. Pure red cell aplasia associated with CD20+ myeloma: complete remission with rituximab.
So CC; Choi WW; Kwong YL
Ann Hematol; 2013 Oct; 92(10):1425-6. PubMed ID: 23494205
[No Abstract] [Full Text] [Related]
15. Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma.
Blatt K; Herrmann H; Stefanzl G; Sperr WR; Valent P
Oncotarget; 2016 Oct; 7(40):65627-65642. PubMed ID: 27582537
[TBL] [Abstract][Full Text] [Related]
16. Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation.
LaCasse EC; Bray MR; Patterson B; Lim WM; Perampalam S; Radvanyi LG; Keating A; Stewart AK; Buckstein R; Sandhu JS; Miller N; Banerjee D; Singh D; Belch AR; Pilarski LM; Gariépy J
Blood; 1999 Oct; 94(8):2901-10. PubMed ID: 10515895
[TBL] [Abstract][Full Text] [Related]
17. The neural cell adhesion molecule NCAM in multiple myeloma.
Kaiser U; Auerbach B; Oldenburg M
Leuk Lymphoma; 1996 Feb; 20(5-6):389-95. PubMed ID: 8833394
[TBL] [Abstract][Full Text] [Related]
18. Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions.
Wen J; Tao W; Kuiatse I; Lin P; Feng Y; Jones RJ; Orlowski RZ; Zu Y
Int J Cancer; 2015 Mar; 136(5):991-1002. PubMed ID: 25042852
[TBL] [Abstract][Full Text] [Related]
19. CD20-positive multiple myeloma - differential expression of cyclins D1 and D2 suggests a heterogeneous disease.
Quinn J; Percy L; Glassford J; Somana K; Rodriguez-Justo M; Yong K
Br J Haematol; 2010 Apr; 149(1):156-9. PubMed ID: 19995388
[No Abstract] [Full Text] [Related]
20. Reply to 'Rituximab in CD20 positive multiple myeloma' by P Moreau et al.
Greipp PT; Kapoor P; Morice WG; Witzig TE; Greipp PR
Leukemia; 2008 Jan; 22(1):214-5. PubMed ID: 17928885
[No Abstract] [Full Text] [Related]
[Next] [New Search]
